Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2006

View Archived Issues

Recent data on HDAC inhibitors in neurological conditions

Preclinical data on actively investigated KSP inhibitor from GSK

Gantacurium pharmacodynamics assessed in phase II trial

Study reveals phenoxodiol effects, mechanism in prostate cancer

Cobra signs CRADA with U.S. Navy for ORT-VAC based malaria vaccine

Rencarex completes phase II study in combination interferon alpha-2a

Phase II study of MF-101 for menopausal symptoms completes enrollment

Enrollment complete in first stage of phase II ALS trial of ALS-08

Auxilium discontinues TestoFilm, reallocates resources to AA-4500

NIH releases strategic plan to guide type 1 diabetes research

SIGA-246 gives 100% protection against human smallpox virus in primate trial

Positive phase III findings for Transacin in postherpetic neuralgia

Genmab updates pipeline progress and future plans

Merck KGaA and Glenmark sign agreement for DPP-IV inhibitor GRC-8200

Bayer and Regeneron to collaborate on VEGF Trap-Eye

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

Recent patents disclose new antiinfective agents

Novel treatment strategies for cancer covered in recent patent literature

Compugen selects three new potential therapeutic candidates

Novel sigma receptor antagonists combat cocaine-induced behavioral toxicity

Preclinical data on Merck's novel CB1 agonist MK-0364 reported at the SfN meeting

Differential modulation of mGluR5 activity yields therapeutic potential in CNS disorders

Seroquel SR filed for approval in Canada, E.U.

Adrovance recommended for approval in E.U.

European CHMP issues positive opinion on Diacomit submission

Tandemact recommended for approval in E.U.

Europe's CHMP recommends Hycamtin for new indication

Positive opinion handed down in Europe for new Glivec indication

Aldara recommended for approval for actinic keratosis in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...